Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto's) thyroiditis : a randomized controlled clinical trial
CONTEXT: Hashimoto's thyroiditis is less prevalent in tobacco smokers. Anatabine, an alkaloid found in Solanaceae plants including tobacco, has been reported to ameliorate a mouse model of Hashimoto's thyroiditis.
OBJECTIVE: The effects of anatabine in patients with Hashimoto's thyroiditis were studied.
DESIGN, SETTING, PATIENTS, AND INTERVENTION: This was a double-blind, randomized, placebo-controlled multisite study. A total of 146 patients (70 treated with anatabine and 76 with placebo) completed the study. Approximately 50% of patients in each group were taking levothyroxine. Anatabine lozenges (9-24 mg/d) or placebo, each containing vitamins A and D3, were administered orally 3 times a day for 3 months.
MAIN OUTCOME MEASURES: Serum thyroperoxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) levels were assessed. Safety was assessed through adverse events, clinical laboratory evaluations, and vital sign measurements.
RESULTS: Anatabine-treated patients had a significant reduction in absolute serum TgAb levels from baseline by study end relative to those receiving placebo (P=.027); however, there were no significant changes or differences in treatment group means for TPOAb or TgAb levels. Mean±SD TgAb values decreased by 46.2±101.1 and 3.9±83.9 World Health Organization units for the anatabine and placebo groups, respectively. Significantly more patients had a >20% drop in TgAb levels in the anatabine than placebo group (P=.023). Overall, the anatabine supplement was safe and well tolerated, although significantly (P<.05) more patients in the anatabine group reported adverse events.
CONCLUSIONS: These results demonstrate an immunological effect of anatabine on TgAb levels. Further studies are warranted to determine the longer-term effects and possible actions of anatabine on the course of Hashimoto's thyroiditis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
The Journal of clinical endocrinology and metabolism - 99(2014), 1 vom: 15. Jan., Seite E137-42 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schmeltz, Lowell R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.03.2014 Date Revised 11.03.2022 published: Print-Electronic ClinicalTrials.gov: NCT01551498 Citation Status MEDLINE |
|---|
| doi: |
10.1210/jc.2013-2951 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM232184976 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM232184976 | ||
| 003 | DE-627 | ||
| 005 | 20231224092433.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/jc.2013-2951 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0774.xml |
| 035 | |a (DE-627)NLM232184976 | ||
| 035 | |a (NLM)24178792 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schmeltz, Lowell R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto's) thyroiditis |b a randomized controlled clinical trial |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2014 | ||
| 500 | |a Date Revised 11.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT01551498 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a CONTEXT: Hashimoto's thyroiditis is less prevalent in tobacco smokers. Anatabine, an alkaloid found in Solanaceae plants including tobacco, has been reported to ameliorate a mouse model of Hashimoto's thyroiditis | ||
| 520 | |a OBJECTIVE: The effects of anatabine in patients with Hashimoto's thyroiditis were studied | ||
| 520 | |a DESIGN, SETTING, PATIENTS, AND INTERVENTION: This was a double-blind, randomized, placebo-controlled multisite study. A total of 146 patients (70 treated with anatabine and 76 with placebo) completed the study. Approximately 50% of patients in each group were taking levothyroxine. Anatabine lozenges (9-24 mg/d) or placebo, each containing vitamins A and D3, were administered orally 3 times a day for 3 months | ||
| 520 | |a MAIN OUTCOME MEASURES: Serum thyroperoxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) levels were assessed. Safety was assessed through adverse events, clinical laboratory evaluations, and vital sign measurements | ||
| 520 | |a RESULTS: Anatabine-treated patients had a significant reduction in absolute serum TgAb levels from baseline by study end relative to those receiving placebo (P=.027); however, there were no significant changes or differences in treatment group means for TPOAb or TgAb levels. Mean±SD TgAb values decreased by 46.2±101.1 and 3.9±83.9 World Health Organization units for the anatabine and placebo groups, respectively. Significantly more patients had a >20% drop in TgAb levels in the anatabine than placebo group (P=.023). Overall, the anatabine supplement was safe and well tolerated, although significantly (P<.05) more patients in the anatabine group reported adverse events | ||
| 520 | |a CONCLUSIONS: These results demonstrate an immunological effect of anatabine on TgAb levels. Further studies are warranted to determine the longer-term effects and possible actions of anatabine on the course of Hashimoto's thyroiditis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Alkaloids |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Placebos |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a anti-thyroglobulin |2 NLM | |
| 650 | 7 | |a anatabine |2 NLM | |
| 650 | 7 | |a 5PP654XB7D |2 NLM | |
| 650 | 7 | |a Iodide Peroxidase |2 NLM | |
| 650 | 7 | |a EC 1.11.1.8 |2 NLM | |
| 700 | 1 | |a Blevins, Thomas C |e verfasserin |4 aut | |
| 700 | 1 | |a Aronoff, Stephen L |e verfasserin |4 aut | |
| 700 | 1 | |a Ozer, Kerem |e verfasserin |4 aut | |
| 700 | 1 | |a Leffert, Jonathan D |e verfasserin |4 aut | |
| 700 | 1 | |a Goldberg, Marc A |e verfasserin |4 aut | |
| 700 | 1 | |a Horowitz, Barry S |e verfasserin |4 aut | |
| 700 | 1 | |a Bertenshaw, Richard H |e verfasserin |4 aut | |
| 700 | 1 | |a Troya, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Amy E |e verfasserin |4 aut | |
| 700 | 1 | |a Lanier, Ryan K |e verfasserin |4 aut | |
| 700 | 1 | |a Wright, Curtis |c 4th |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical endocrinology and metabolism |d 1945 |g 99(2014), 1 vom: 15. Jan., Seite E137-42 |w (DE-627)NLM00001821X |x 1945-7197 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2014 |g number:1 |g day:15 |g month:01 |g pages:E137-42 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1210/jc.2013-2951 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2014 |e 1 |b 15 |c 01 |h E137-42 | ||